TY - JOUR T1 - Lipid Peroxide–Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1441 LP - 1449 DO - 10.1124/dmd.115.065136 VL - 43 IS - 10 AU - Chungang Gu AU - Richard J. Lewis AU - Andrew S. Wells AU - Per H. Svensson AU - Vinayak P. Hosagrahara AU - Eskil Johnsson AU - Gösta Hallström Y1 - 2015/10/01 UR - http://dmd.aspetjournals.org/content/43/10/1441.abstract N2 - This study focused on the mechanistic interpretation of ex vivo oxidation of a candidate drug in blood plasma samples. An unexpected lipid peroxide–mediated epoxidation followed by a dramatic rearrangement led to production of a five-membered oxazole derivative from the original six-membered pyrazinone-carboxamide core of a human neutrophil elastase inhibitor, 6-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-N-ethyl-5-methyl-3-oxo-4-(3-(trifluoromethyl)phenyl)-3,4-dihydropyrazine-2-carboxamide (AZD9819). The rearranged oxidation product 2-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-5-(N-ethylacetamido)-N-(3-(trifluoromethyl)phenyl)oxazole-4-carboxamide was characterized by accurate-mass tandem mass spectrometry fragmentations, by two-dimensional NMR and X-ray crystallography of an authentic standard, and by incorporation of an 18O atom from molecular 18O2 to the location predicted by our proposed mechanism. The lipid peroxide–mediated oxidation was demonstrated by using human low-density lipoprotein (LDL) in pH 7.4 phosphate buffer and by inhibiting the oxidation with ascorbic acid or l-glutathione, two antioxidants effective in both plasma and the LDL incubation. A nucleophilic mechanism for the epoxidation of AZD9819 by lipid hydroperoxides explains the prevention of its ex vivo oxidation by acidification of the plasma samples. The discovery of the lipid peroxide–dependent oxidation of an analyte and the means of prevention could provide valuable information for biotransformation and bioanalysis. ER -